Redeye returns with an updated view of Saniona following the Q3 report and the transformative licensing deal with Acadia. We raise our base case effective immediately and include the new indication (essential tremor) for SAN711 and an initial valuation of SAN2355, the preclinical epilepsy candidate that is soon ready to enter the clinic.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/